Literature DB >> 17245597

The impact of different chelating leaving groups on the substitution kinetics of mononuclear Pt(II)(1,2-trans-R,R-diaminocyclohexane)(X-Y) complexes.

Nadine Summa1, Tanja Soldatović, Lutz Dahlenburg, Zivadin D Bugarcić, Rudi van Eldik.   

Abstract

A set of three oxaliplatin derivatives containing 1,2-trans-R,R-diaminocyclohexane (dach) as a spectator ligand and different chelating leaving groups X-Y, viz., [Pt(dach)(O,O-cyclobutane-1,1-dicarboxylate)], or Pt(dach)(CBDCA), [Pt(dach)(N,O-glycine)]+, or Pt(dach)(gly), and [Pt(dach)(N,S-methionine)]+, or Pt(dach)(L-Met), where L-Met is L-methionine, were synthesized and the crystal structure of Pt(dach)(gly) was determined by X-ray diffraction. The effect of the leaving group on the reactivity of the resulting Pt(II) complexes was studied for the nucleophiles thiourea, glutathione (GSH) and L-Met under pseudo-first-order conditions as a function of nucleophile concentration and temperature, using UV-vis spectrophotometric techniques. 1H NMR spectroscopy was used to follow the substitution of the leaving group by guanosine 5'-monophosphate (5'-GMP2-) under second-order conditions. The rate constants indicate for all reactions a direct substitution of the X-Y chelate by the selected nucleophiles, thereby showing that the nature of the chelate, viz., O-O (CBDCA2-), N-O (glycine) or S-N (L-Met), respectively, plays an important role in the kinetic and mechanistic behavior of the Pt(II) complex. The k1 values for the reaction with thiourea, L-Met, GSH and 5'-GMP2- were found to be as follows (10(3) k1, 37.5 degrees C, M(-1) s(-1)): Pt(dach)(CBDCA) 61 +/- 2, 21.6 +/- 0.1, 23 +/- 1, 0.352 +/- 0.002; Pt(dach)(gly) 82 +/- 3, 6.2 +/- 0.2, 37 +/- 1, 1.77 +/- 0.01; Pt(dach)(L-Met) (thiourea, GSH) 62 +/- 2, 24 +/- 1. The activation parameters for all reactions studied suggest an associative substitution mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245597     DOI: 10.1007/s00775-006-0200-z

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.862


  17 in total

1.  Current status of platinum-based antitumor drugs.

Authors:  E Wong; C M Giandomenico
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.

Authors:  Georg Lenz; Ulrich T Hacker; Wolfgang Kern; Andreas Schalhorn; Wolfgang Hiddemann
Journal:  Anticancer Drugs       Date:  2003-10       Impact factor: 2.248

3.  Substitution reactions of [Pt(terpy)X]2+ with some biologically relevant ligands. Synthesis and crystal structure of [Pt(terpy)(cyst-S)](ClO4)2.0.5H2O and [Pt(terpy)(guo-N7)](ClO4)2.0.5guo.1.5H2O.

Authors:  Zivadin D Bugarcic; Frank W Heinemann; Rudi van Eldik
Journal:  Dalton Trans       Date:  2003-12-03       Impact factor: 4.390

4.  Thermodynamic and kinetic studies on reactions of Pt(II) complexes with biologically relevant nucleophiles.

Authors:  Nadine Summa; Wolfgang Schiessl; Ralph Puchta; Nico van Eikema Hommes; Rudi van Eldik
Journal:  Inorg Chem       Date:  2006-04-03       Impact factor: 5.165

5.  Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.

Authors:  Britta K Stordal; Mary W Davey; Ross A Davey
Journal:  Cancer Chemother Pharmacol       Date:  2005-11-10       Impact factor: 3.333

6.  Analysis of cytotoxicities of platinum compounds.

Authors:  Jerry Goodisman; Douglas Hagrman; Kirk A Tacka; Abdul-Kader Souid
Journal:  Cancer Chemother Pharmacol       Date:  2005-07-19       Impact factor: 3.333

7.  Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS).

Authors:  AnnaRita Ghezzi; Maurizio Aceto; Claudio Cassino; Elisabetta Gabano; Domenico Osella
Journal:  J Inorg Biochem       Date:  2004-01       Impact factor: 4.155

8.  Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

Authors:  B D Evans; K S Raju; A H Calvert; S J Harland; E Wiltshaw
Journal:  Cancer Treat Rep       Date:  1983-11

9.  Kinetic study on the reactions of platinum drugs with glutathione.

Authors:  Douglas Hagrman; Jerry Goodisman; Abdul-Kader Souid
Journal:  J Pharmacol Exp Ther       Date:  2003-11-10       Impact factor: 4.030

Review 10.  Tumour-inhibiting platinum complexes--state of the art and future perspectives.

Authors:  M A Jakupec; M S Galanski; B K Keppler
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-02-04       Impact factor: 7.500

View more
  4 in total

1.  Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.

Authors:  Irina Buß; Ganna V Kalayda; Andreas Lindauer; Michael R Reithofer; Markus Galanski; Bernhard K Keppler; Ulrich Jaehde
Journal:  J Biol Inorg Chem       Date:  2012-03-29       Impact factor: 3.358

2.  Kinetics and mechanism of the substitution reactions of [PtCl(bpma)]+, [PtCl(gly-met-S,N,N)] and their aqua analogues with L-methionine, glutathione and 5'-GMP.

Authors:  Zivadin D Bugarcić; Jovana Rosić; Biljana Petrović; Nadine Summa; Raph Puchta; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

3.  A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells.

Authors:  Malay Patra; Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Angew Chem Int Ed Engl       Date:  2016-01-08       Impact factor: 15.336

4.  Oxaliplatin reacts with DMSO only in the presence of water.

Authors:  Hristo P Varbanov; Daniel Ortiz; Doris Höfer; Laure Menin; Mathea S Galanski; Bernhard K Keppler; Paul J Dyson
Journal:  Dalton Trans       Date:  2017-07-18       Impact factor: 4.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.